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Abstract 
The physiological mechanisms that confer different outcomes in morbidity and 
mortality of the fetus exposed to stressful environments may be driven by significant 
differences in the expression and function of the placental glucocorticoid receptor (GR). The 
recent discovery that the placenta contains at least 8 different isoforms of the GR raises 
questions about the regulation and physiological relevance of the many GR variants 
expressed in the placenta. The current data also highlights that individual differences in 
glucocorticoid sensitivity, variations in the effect of different complications of pregnancy on 
birth outcomes and sex differences in the response to stress, may all be dependent on a 
specific GR isoform expression profile. This review will investigate the current state of 
knowledge of GR isoforms in the placenta and discuss the potential role of these multiple 
isoforms in regulating glucocorticoid sensitivity.  
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Introduction  
Glucocorticoids derived from the adrenal are essential for homeostatic adaptation to 
stress, especially severe stress associated with acute and complicated diseases. Preserving 
optimum action of glucocorticoids at target tissues during a stress related event is vital for the 
maintenance of cellular and organ homeostasis[1]. Insufficient bioactivity of glucocorticoids 
has been associated with adverse outcomes and death in relation to events such as infection, 
septicaemia and major injury [1]. In pregnancy, glucocorticoids derived from the maternal 
system and acting via the placenta are essential for the maturation, development and survival 
of the fetus in all mammalian species [2]. However exposure to maternal stress and excess 
glucocorticoids in utero can be detrimental to fetal growth, development and survival. 
Cortisol, the primary endogenous glucocorticoid in humans, is often elevated in women 
exposed to perturbations such as hypoxia, alcohol consumption, malnutrition, asthma and 
anxiety. In addition, synthetic glucocorticoids are frequently administered to women at risk of 
preterm delivery as well as those with conditions such as systemic lupus erythematosus and 
hyperemesis gravidarum (reviewed by [3]). Numerous studies have demonstrated that 
maternal exposure to increased endogenous or synthetic glucocorticoids can lead to fetal 
growth restriction [2] and have long term consequences for the health of live offspring [4-6].  
The physiological mechanisms that confer different outcomes in morbidity and 
mortality of the fetus exposed to stressful environments may be driven by significant 
differences in the pattern of expression of placental glucocorticoid receptor (GR) isoforms 
[7]. The GR has been recognised as central to maintenance of tissue specific glucocorticoid 
responsivity with the interaction of different GR isoforms conferring differences in organ 
sensitivity[7]. It has been identified that there are multiple GR protein isoforms in the 
placenta of the human [8, 9] and guinea pig [10] that vary in relation to gestational age at 
delivery, sex, glucocorticoid exposure, fetal growth and maternal health. These multiple 
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isoforms may in fact confer differences in glucocorticoid sensitivity under different 
conditions and complications of pregnancy. This review will investigate the current state of 
knowledge of GR isoforms in the placenta in association with different complications of 
pregnancy and the potential role of these multiple isoforms in regulating glucocorticoid 
sensitivity and the long term impact on health. 
 
Glucocorticoids in pregnancy and impact on fetal growth and lifelong health 
Glucocorticoids derived from the maternal system play a central role in fetal growth and 
organ maturation. Maternal stress, mental illness or disease states that promote higher 
circulating concentrations of maternal cortisol (e.g. through decreased placental metabolism 
of glucocorticoids) can perturb fetal development of the cardiovascular system, the kidney, 
the brain and the immune system [11] [12]. This, in turn, may contribute to an increased risk 
of cardiovascular, renal, neurological, respiratory and metabolic disorders as well as allergy 
in later life [13]. The mechanisms by which excess maternal cortisol concentrations program 
fetal organ deficits remain undefined, although these effects appear to be induced in a sex-
specific manner and via alterations in placental function [14]. This has been supported by 
work performed in animal studies whereby maternal stress or maternal exposure to cortisol 
(or corticosterone in rodents) induces sex specific dysregulation of placental function [15, 16] 
and offspring disease outcomes [5, 17, 18]. These studies indicate that an optimal placental 
response to maternally produced glucocorticoids is an essential part of fetal growth and 
development.  
Excess exposure to synthetic glucocorticoids during pregnancy can also significantly 
impact lifelong health. Adverse consequences for preterm neonates exposed to 
glucocorticoids have been reported, and include an altered stress response [19], altered motor 
development and neuropsychological function in adolescence [20] and higher blood pressure 
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[21]. Studies in rodents have similarly demonstrated that maternal exposure to synthetic 
glucocorticoids leads to sex specific placental adaptations [22, 23] and offspring disease 
outcomes [24, 25]. Sheep studies have demonstrated that synthetic glucocorticoids were more 
effective at inducing fetal lung maturation when administered to the mother than when 
administered directly to the fetus [26]. However maternal betamethasone administration also 
resulted in a fetal growth reduction [27] suggesting that excess maternal glucocorticoids may 
exert some of its effects on the fetus via changes in placental function [28]. Subsequent sheep 
studies have identified increased placental apoptosis [29] and decreased circulating insulin-
like growth factor concentrations [30] following maternal betamethasone exposure which 
may influence placental nutrient transport and fetal growth. Importantly, studies in sheep and 
mice have demonstrated quite different outcomes in offspring exposed endogenous 
glucocorticoids compared to synthetic glucocorticoids [15, 22, 31]  Understanding the 
mechanisms by which excess cortisol or synthetic glucocorticoid exposure impacts on fetal 
development begins with the GR and its downstream signalling pathways [32-34]. It is 
important to note that a variety of maternal perturbations have been shown to disrupt the 
regulation of the GR through multiple mechanisms. Indeed, studies have highlighted that 
epigenetic regulation of mammalian Nr3c1, the gene that encodes the GR may contribute to 
the sex specific regulation of glucocorticoid mediated outcomes [35] both during pregnancy 
and into adult life. We propose that different patterns of placental GR isoform expression [8, 
9] regulate placental mechanisms associated with fetal growth, influence perinatal outcomes 
and programed long term health.  
 
The glucocorticoid receptor 
The GR is part of the nuclear receptor transcription factor super family and is expressed in 
most cells in the body. Until recently, the regulation of GR mediated gene expression was 
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thought to be predominantly controlled by GRα-A until GRβ was demonstrated to play a key 
role in regulating placental responses to a challenge [36]. The human GR gene is comprised 
of 9 exons with exon 1 containing the 5’ untranslated region which can be spliced into 9 
different promoter variants [37] that function in a tissue specific manner to regulate GR 
protein expression. Exon 2 of the GR gene has 8 translation start sites that result in the 
formation of eight different GRα translational isoforms that include GRα-A, GRα-B, GRα 
C1-C3 and GRα D1-D3 proteins. GRα A is the most studied isoform and is involved in 
transcriptional activation and transcriptional repression of multiple gene targets. However, all 
translated GRα variants have the ability to translocate into the nucleus to regulate 
transcriptional activities. Exons 2-9 can generate various isoforms of GR through alternative 
splicing resulting in the expression of GRα, GRβ, GRγ, GR-A and GR-P proteins. GRβ 
inhibits activation of GRα through a dominant negative mechanism but has also been shown 
to stimulate growth [38] and regulate metabolism in the mouse [39]. Splice variants GRγ, 
GR-A and GR-P have low transactivation activities [40, 41] but may still have an essential 
role in determining which glucocorticoid regulated genes are activated. The presence of exon 
2 in each of the splice variants means there may also be translational isoforms of the splice 
variants though these have yet to be identified. These different GR isoforms are likely to 
regulate downstream activity differently depending on glucocorticoid type and dose with 
different outcomes dependent on GR isoform interactions with other proteins which may be 
tissue and sex dependent.  
 
Mechanisms that regulate glucocorticoid sensitivity: role of the GR  
Given that glucocorticoids are capable of regulating up to 20% of genes encoded in 
the genome [42], multiple factors have evolved to regulate how a cell responds to 
glucocorticoids. There are several mechanisms that confer either sensitivity or resistance to 
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glucocorticoids pre- and post-receptor. Prior to activation of the receptor, there are a number 
of pathways that limit cellular exposure to active glucocorticoids. The enzyme 11β 
hydroxysteroid dehydrogenase type 2 (11βHSD2)[43] is known to at least partially regulate 
placental and fetal glucocorticoid exposure and impart glucocorticoid specificity in organs 
where both mineralocorticoids and glucocorticoids regulate cellular function. The multidrug 
resistance protein, glycoprotein P (Pgp)[44] similarly infers some degree of glucocorticoid 
resistance by actively exporting glucocorticoids into the maternal circulating and preventing 
placental and fetal glucocorticoid exposure. In addition, proteins that bind glucocorticoids 
[45] such as cortisol binding globulin (CBG) and albumin regulate bioavailability of 
glucocorticoids in various tissues with different glucocorticoid binding potential depending 
on the presence of other hormones [46]. The fact that there are multiple mechanisms for 
regulating placental exposure to active glucocorticoids highlights the importance of 
regulating placental and fetal glucocorticoid exposure, however, these factors alone are not 
sufficient to account for differences in the cortisol response observed between sexes and in 
relation to pregnancy complications such as preterm delivery, maternal asthma and small-for-
gestational age (SGA) fetuses. This has led to the examination of the placental glucocorticoid 
receptor (GR) in more detail.  
 
Placental GR isoforms  
Previous studies have demonstrated that mRNA levels of a number of splice variants 
of the GR are detectible in the human placenta, including GRβ, GR-P and GRγ [47]. 
Dexamethasone and cortisol exposure in vitro have both been shown to downregulate GRα 
and GR P mRNA expression [47]. In pregnancies complicated by asthma, placental GR gene 
activity (as determined by heteronuclear RNA levels) is positively correlated with cord blood 
cortisol concentrations [33]. Moreover, GR isoform patterns likely mediate sex-specific 
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differences in the placental sensitivity of glucocorticoid-regulated pathways [22, 48] where 
female placentae are more sensitive to changes in glucocorticoid concentrations than male 
placentae. Unexpectedly, these differences in glucocorticoid sensitivity are not related to any 
sex-specific differences in GRα-A protein expression [33, 48] which suggests that other GR 
isoforms may play a key role and explain why some placentae are more responsive to 
glucocorticoids than others under the same environmental conditions.  
We have identified a novel mechanism to explain how different placentae have varied 
glucocorticoid responses from studying a range of complications including pregnancies of 
asthmatic women, preterm deliveries and small for gestational age fetuses (SGA) [8, 9]. The 
human placental trophoblast expresses 8 known placental GR isoforms including GRα-A, 
GRβ, GRα-C, GRP, GRA, and GRα-D1-3. The data shows that GR isoform expression varies 
with cell type, cellular location, and by the specific complications affecting the pregnancy [8, 
9]. From these findings it appears that glucocorticoid responsivity in a high glucocorticoid 
environment is dependent on the presence or absence of the splice variants GRβ, GR P and 
GR A [8, 9]. It is now important to examine the co-expression and interaction of different GR 
isoforms in placental tissues to determine what impact these GR isoform patterns have on 
downstream signalling pathways.  
 
 
GR isoform interactions in pregnancy complications  
Different downstream pathways and target genes can be activated when different GR 
isoforms are expressed alone or in combination with other GR isoforms [49, 50]. A clear and 
well characterised example of the differential effects of isoforms expressed alone versus in 
combination is when GRα-A and GRβ are co-expressed in neutrophils. In these cells, both 
GRα-A and GRβ are expressed under baseline conditions but when cells are exposed to IL-8 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
there is an increase in GRβ and a decrease in corticosteroid-induced apoptosis [51]. Based on 
published evidence, it appears that a male fetus from pregnancies complicated by asthma may 
continue to grow in a high glucocorticoid environment due to the co-expression of GRβ and 
GRα-A [8] which possibly upregulates growth related genes. In high glucocorticoid 
environments where female fetal growth is compromised, it appears that glucocorticoid 
sensitivity is maintained through an interaction of GRα-A with GRα-C or GRα-D, potentially 
driving increased apoptosis and contributing to reduced fetal growth. 
 
The expression of placental GR isoforms also varies in relation to gestational age and fetal 
sex [9]. Male preterm placentae have higher cytoplasmic levels of GRα-C and GR-A relative 
to term male placentae. Female preterm placentae had higher levels of nuclear GRα C relative 
to term placentae. GRα-C is the most potent activator of glucocorticoid induced apoptosis 
which involves activation of the mitochondrial BIM pathway leading to caspase 9 and 3 
activation and cell death. Increased expression of BIM and BAD have been identified in the 
placenta of preterm placenta. The increased expression of GRα-C may be significant in 
understanding the pathophysiology of preterm delivery where an increase in glucocorticoid-
induced cell death mediated by GRα-C may be initiated prior to preterm labour[8].  
 
GRα-A is only expressed 70% of the time in placentas of preterm fetuses and relative to the 
other isoforms, GRα-A expression accounts for less than 2% of all GR expression[8].  Even 
so, GRα A may still have a biological function as it was negatively correlated with preterm 
female placental weight suggesting cortisol may regulate placental growth via GRα-A. Other 
studies have reported that exposure of the placenta to cortisol in the absence of glucocorticoid 
metabolism results in decreased placental growth[52]. In addition, exposure to betamethasone 
for threatened preterm labour can reduce placental size by 6% which could be mediated by 
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GRα-A[53]. However other isoforms were also negatively associated with female placental 
weight including GRα-C and GR-P which suggests several isoforms may interact to influence 
placental growth[9]. Placental betamethasone exposure in pregnancies associated with 
preterm delivery did not affect the expression of any of the known GR isoforms in either 
male or female human preterm placentae. This may not be a true effect of betamethasone but 
a result of the variability in GR expression between placentae related to the timing of 
exposure to betamethasone and birth.   
 
In term placentae associated with a SGA fetus ( SGA, <10th birthweight centile), cytoplasmic 
and nuclear expression of GRβ and nuclear expression of GRα-D1 were significantly higher 
[8]. In preterm, SGA female placentae there was decreased expression of nuclear GR-A and 
GRα-D2 and decreased cytoplasmic GRα-D1[9]. GRβ and GR-A have both been 
characterised to act as glucocorticoid antagonists while the GRα-D isoforms are known to 
have low trans-activational activities[7, 8]. Given SGA is associated with high circulating 
levels of cortisol and increased inflammation[54], it is possible the placental pathophysiology 
of SGA pregnancies are mediated through reduced responsivity to glucocorticoids through 
the expression of antagonistic GR isoforms that do not mediate the anti-inflammatory effects 
of glucocorticoids. 
 
Epigenetics and GR regulation 
The human GR (NR3C1) 5’ untranslated region contains nine exon 1 variants (1A, 
1B, 1C, 1D, 1E, 1F, 1H, 1I and 1J) that display tissue-specific expression [37, 55]. Exons 1A 
and 1C additionally have three splice variants each, named 1A1 to 1A3 and 1C1 to 1C3. 
Exon 1 variants detected in human placentae include 1A3, 1B, 1C, 1D, 1F and 1J [55]. Each 
exon 1 variant has a proximal promoter which controls its expression in a cell type-specific 
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manner [56]. Seven of the exon 1 variants (1B-1H and 1J) are also located in a CpG 
dinucleotide-rich region known as a CpG island, and in vitro reporter assays have shown that 
promoter cytosine methylation can confer an extra level of transcriptional control, with 
hypermethylation associated with promoter silencing [56]. There is widespread interest in 
epigenetics, including DNA methylation, as a potential mechanism for the effects of early-life 
events on long-term health outcomes. Consistent with this, reports have linked methylation 
changes at the placental GR gene promoter to maternal smoking [57] and stress [58] as well 
as offspring birthweight [59] and neurodevelopment [60]; however, the effect on GR 
expression was not examined in vivo. Interestingly, studies have correlated the expression of 
particular exon 1 variants with specific GR protein isoforms in various tissues [61] including 
placenta [47]. Although the basis for this link is unknown, a corollary is that GR exon 1 
variant promoter DNA methylation would also influence which GR isoforms are expressed in 
the placenta, possibly mediating the effects of pregnancy complications on the fetus. 
 
Placental GR isoforms in animal models  
The presence of multiple GR isoforms in the placenta is not limited to the human. There are 8 
known GR isoforms in the placentae of the guinea pig with expression being affected by fetal 
sex, gestational age and betamethasone exposure [10]. The 8 known isoforms identified in the 
guinea pig placenta were GRγ, GRα-A, GRβ, GRP, GRA, GRα D1-3 with GRα-B absent due 
to the fact that the second start codon on exon 2 of the guinea pig GR gene contains an 
isoleucine codon instead of methionine. Using this animal model, the physiological and 
pathophysiological significance of the multiple GR isoforms on placental function and fetal 
development have been investigated with the long term goal of testing the efficacy of 
selective GR isoform modulators. When betamethasone was administered to pregnant Guinea 
pigs cytoplasmic expression of GRα-A, GRβ, GRα-D1 and D3 and nuclear expression of 
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GRα-A, GRβ and GRα-D3 were increased regardless of sex or gestational age. 
Betamethasone exposure specifically affected GRα-A expression in preterm but not term 
animals indicating there may be gestational age specific effects of synthetic glucocorticoids 
on GR bioactive isoforms. However GRβ, GR-A and GRα-D were also increased with 
betamethasone exposure in preterm placentae suggesting there may be competitive inhibition 
of GRα-A actions. Overall the data suggests that antagonistic GR isoforms and low trans-
activational isoforms of GR are increased in the presence of high circulating levels of 
betamethasone which may be a protective mechanism against the potential detrimental effects 
of excess glucocorticoid exposure that can inhibit growth, reduce nutritional supply and 
inhibit inflammation reducing the capacity of the placenta to resist infection. 
 
Given that at least 8 GR isoforms can be detected in placentae of two species as genetically 
different as humans and guinea pigs, it is likely that a similar number of isoforms may infer 
GR sensitivity in other species. While the guinea pig is now routinely being used in fetal 
programming studies, the majority of glucocorticoid exposure models have been performed 
in rats, mice and sheep. Therefore, it is important to identify GR isoforms within these 
models to better understand how glucocorticoids mediate sex-specific disease outcomes.  
Early studies in sheep demonstrated multiple GR isoforms in the adult adrenal gland [62] and 
indeed studies have demonstrated the presence of at least three GR isoforms in the sheep 
placenta [63]. Given that the human, monkey, mouse and rat all have the second start codon 
on exon 2 that the guinea pig is missing, it is likely that the monkey, mouse and rat would 
have a GR expression profile similar to that of human. Indeed, studies in mice have 
demonstrated a number of GR isoforms in non-reproductive tissues [64]. Preliminary data 
indicates that the mouse placenta expresses at least 8 known GR isoforms including GRα-A, 
C, D1-3, GR-A, GR-P and GRβ [65]. These isoforms are likely to be altered by fetal sex as 
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well as exposure to glucocorticoids and may explain the glucocorticoid and sex dependant 
placental adaptations that mediate programmed disease outcomes.  
 
Conclusion 
These studies highlight that our understanding of placental responses to glucocorticoids are 
likely to be dependent on the interactions of multiple GR isoforms. The physiological 
significance of multiple isoforms in the placenta and their role in downstream signaling are 
the subject of current investigations. It is also important to note that even though some GR 
isoforms change significantly in the placenta, other GR isoforms appear stable and could also 
influence glucocorticoid bioactivity and sensitivity. Most certainly these studies suggest that 
there are specific GR protein profiles that may confer specific differences in placental 
glucocorticoid responsivity that vary in relation to the pregnancy complication, the sex of the 
fetus and even between individuals.  
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Table 1: Expression and localisation of human placental GR isoforms in relation to fetal 
sex and pregnancy outcomes 
 Nuclear GR 
isoforms  
 Cytoplasmic 
GR isoforms 
 
 
 Females Males Females Males 
Term Pregnancy GRα A + 
GRα D1 +  
68 kDa + 
GRα A + 
GR P + 
GR A + 
  
Preterm Pregnancy GRα C + 
48 kDa + 
 
GRα D2 + 
 
48 kDa + 
38 kDa + 
GRα C + 
GR A + 
48 kDa - 
Betamethasone 
exposure in 
preterm 
48 kDa +    
Preterm small for 
gestational age 
GRα D2 - 
GR A- 
 
 GRα D1 - 
48 kDa - 
 
Maternal asthma GRα A + 
GRα D1 +  
GRα D3 + 
 GRα C + 
GRα D1 + 
GRα D3 + 
GRβ + 
 
Legend: + : increased expression; - : decreased expression 
 
 
 
